$HUMA News

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

Humacyte Reports Results From Its V012 Phase 3 Trial Of Bioengineered Blood Vessel At Society For Vascular Surgery's Vascular Annual Meeting

HC Wainwright & Co. Maintains Buy on Humacyte, Raises Price Target to $4

Why Is Humacyte Stock Falling Thursday?

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Humacyte Commences Common Stock Offering; Terms Not Disclosed

Humacyte Announces Positive Interim Results From Phase Study Of Acellular Tissue Engineered Vessel In Female Patients For Dialysis Access, To Present Results June 11

BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target

Humacyte (HUMA) Q1 2025 Earnings Transcript

Benchmark Maintains Speculative Buy on Humacyte, Raises Price Target to $2